Hydra Biosciences, Inc. And Boehringer Ingelheim Corporation Announce Worldwide Collaboration To Develop Small-Molecule Inhibitors For The Treatment Of Central Nervous System Diseases And Disorders

CAMBRIDGE, Mass. & INGELHEIM, Germany--(BUSINESS WIRE)--Hydra Biosciences, Inc., a leader in the field of Transient Receptor Potential (TRP) channel modulation, and Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, jointly announced today that they have entered into a worldwide collaboration to research and develop small-molecule TRPC4/5 inhibitors for the treatment of central nervous system (CNS) diseases and disorders.

Help employers find you! Check out all the jobs and post your resume.